Optimal Timing for Laparoscopic Cholecystectomy After Cholecystostomy in Acute Cholecystitis Tokyo II/III Setting

NCT ID: NCT06476054

Last Updated: 2024-06-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 146 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-01
• Study Completion Date: 2027-08-01

Brief Summary

Percutaneous drainage in acute cholecystitis has been recommended by the recent update of the Tokyo Guidelines for patients with grade II and III disease who are unable to undergo surgical treatment due to their condition or associated comorbidities.

There are no reports providing high-quality scientific evidence on the optimal timing for surgery after percutaneous transhepatic gallbladder drainage, so a consensus has not been reached. The grade III stage generates the most controversy; after percutaneous drainage, delaying the cholecystectomy can lead to new episodes of exacerbation during the waiting period or may limit the procedure to a specific group of patients with this pathology.

The economic impact, including the number of readmissions, increased length of stay, and associated morbidity and mortality, generates controversy regarding the subsequent therapeutic decisions after the medical management of cholecystitis in this special group of patients.

Detailed Description

A multicentric, blinded, parallel clinical trial is proposed to compare early and late cholecystectomy after percutaneous cholecystostomy (PC).

The primary objective of the present study is to determine the ideal time interval-early versus late-for performing laparoscopic cholecystectomy (LC) in patients who underwent PC. This includes assessing whether recurrence can be reduced. As a secondary aim, to analyze the morbidity and mortality associated with the intervention.

Recruitment and Deadlines

Only surgical departments with an adequate number of patients will be included in the trial to ensure the sample size objective. The selected recruitment period is 18 months.

Study Variables

Surgical sheets, laboratory reports, daily notes made by hospital staff, discharge summaries, and outpatient clinic notes will be reviewed. Pre-operative characteristics, including sex, age, body mass index (BMI), comorbidities (diabetes mellitus, asthma, chronic obstructive pulmonary disease, malignant neoplasms, and immunosuppressive therapy), the main procedure performed as well as secondary procedures such as endoscopic retrograde cholangiopancreatography (ERCP) after confirming choledocholithiasis with magnetic resonance cholangiopancreatography (MRCP), will be collected. Variables related to the pre-operative context of the patient, such as Intensive Care Unit (ICU) admission, the patient's hemodynamic status, the presence of septic shock, and the need for vasoactive drugs, will also be collected. The characteristics studied for laparoscopic cholecystectomy (LC) were as follows: type of prophylactic antibiotics used, details of the LC surgical technique, intraoperative complications, assessment of technical difficulty (as there are no quantitative scales, relied on previous studies adapted according to our group's consensus) defined as: 1. Need for conversion, 2. Atypical cholecystectomy (e.g., subtotal), 3. Strong adhesions on the gallbladder, 4. Difficult dissection of the hilar region due to chronic inflammatory processes, and 5. Increased average surgery time. Postoperative characteristics recorded included: hospital stay, postoperative complications and treatments, bile cultures, subsequent complications, need for reoperation, 30 and 90-day morbidity and mortality, and total follow-up time.

Interventions

Pre-operative Study

All participants with PC will undergo a preoperative study using MRCP or endoscopic ultrasound (EUS) to rule out associated choledocholithiasis. A second MRCP or EUS will be planned for the delayed group just before LC. If choledocholithiasis is confirmed, preoperative endoscopic retrograde cholangiopancreatography (ERCP) will be performed.

Prophylactic Pre-operative Antibiotherapy

Prophylactic antibiotherapy will be administered according to hospital protocol

PC Catheter Removal

Various publications have proposed the removal of the PC catheter after confirming the clinical resolution of acute cholecystitis (AC) following PC, performing percutaneous cholangiography between the third and fourth day of the procedure to evaluate the patency of the cystic duct. If continuity is confirmed, the catheter will be removed after the completion of antibiotic treatment and 24 hours before clinical discharge; otherwise, it will remain until the surgical intervention. In the present study, to avoid biases related to the catheter's permanence between groups or complications associated with its removal, the catheter will remain until the day of LC, and its removal will be performed intraoperatively under direct vision. The tip of the PC catheter will be sent for culture.

Randomization and Blinding

Prior to inclusion in the trial, the certified investigator from the Surgical Department will perform the screening and gather patient information and informed consent. An online tool will be provided to generate the sequence for group assignment, stratified by the grade of AC at the time of PC placement.

According to the interval for surgical intervention:

• Early LC group: Less than 2 weeks (within the first 2 weeks of diagnosis, after confirming CA resolution or improvement of functional status and coagulation that allows LC to be performed under optimal conditions), preferably within the first 10 days from the onset of CA symptoms.
• Delayed LC group: From the 6th week (preferably between the 6th and 8th weeks of CA diagnosis).

Randomization sheets will be kept outside the patient's medical records. The primary objective (reduction of recurrence - in a previous study of the group it is up to 20% - with this data and assuming a reduction from 20% to 5% for those cannot be operated, 73 patients per group will be needed) will be clinically evaluated by a local group member who will not be part of the surgical team performing the intervention nor will have access to the randomization results to maintain blinding. In case of risk to the patients included in the study, access to randomization data will be allowed to the local investigator.

Conditions

Cholecystitis, Acute

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

early interval

Both arms involve interventions, but participants in the early interval arm will undergo treatment (laparoscopic cholecystectomy) within 2 weeks after diagnosis, preferably within 10 days after the onset of symptoms of acute cholecystitis.

Group Type: OTHER

Optimal timing for laparoscopic cholecystectomy

Intervention Type: PROCEDURE

To compare early and late cholecystectomy after cholecystostomy.

late interval

Both arms involve interventions, but participants in the late interval arm will undergo treatment (laparoscopic cholecystectomy) after the 6th week of diagnosis, ideally between week 6 and week 8 following the diagnosis of acute cholecystitis.

Group Type: OTHER

Optimal timing for laparoscopic cholecystectomy

Intervention Type: PROCEDURE

To compare early and late cholecystectomy after cholecystostomy.

Interventions

Optimal timing for laparoscopic cholecystectomy

To compare early and late cholecystectomy after cholecystostomy.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• patients over 18 years of age
• patients candidates for cholecystectomy, in scheduled surgery
• patients who accept participation and sign informed consent form

Exclusion Criteria

• According to the principal investigator criteria, for reasons that make it impossible to correctly follow the treatment.
• Presence of morbidity associated with the procedure that delays or makes treatment impossible.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospital Arnau de Vilanova

OTHER

Sponsor Role: lead

Responsible Party

FULTHON FRANK VELA POLANCO

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

605387406 Vela Polanco, Dr

Role: PRINCIPAL_INVESTIGATOR

Hospital Arnau de Vilanova

Locations

Hospital Universitari Arnau de Vilanova

Lleida, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Fulthon Frank Vela Polanco, Dr

Role: CONTACT

ffvela.lleida.ics@gencat.cat

0034605387406

Facility Contacts

Nuria Badia

Role: primary

recercaicsgsslleida@gencat.cat

0034667045245

Other Identifiers

2453

Identifier Type: -

Identifier Source: org_study_id